It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The tight junction protein claudin-3 has been identified as a transcriptional target of the Wnt/β-catenin signaling pathway regulating blood-brain barrier (BBB) maturation. In neurological disorders loss of claudin-3 immunostaining is observed at the compromised BBB and blood-cerebrospinal fluid barrier (BCSFB). Although these observations support a central role of claudin-3 in regulating brain barriers’ tight junction integrity, expression of claudin-3 at the brain barriers has remained a matter of debate. This prompted us to establish claudin-3−/− C57BL/6J mice to study the role of claudin-3 in brain barrier integrity in health and neuroinflammation. Bulk and single cell RNA sequencing and direct comparative qRT-PCR analysis of brain microvascular samples from WT and claudin-3−/− mice show beyond doubt that brain endothelial cells do not express claudin-3 mRNA. Detection of claudin-3 protein at the BBB in vivo and in vitro is rather due to junctional reactivity of anti-claudin-3 antibodies to an unknown antigen still detected in claudin-3−/− brain endothelium. We confirm expression and junctional localization of claudin-3 at the BCSFB of the choroid plexus. Our study clarifies that claudin-3 is not expressed at the BBB and shows that absence of claudin-3 does not impair brain barrier function during health and neuroinflammation in C57BL/6J mice.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Bern, Theodor Kocher Institute, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
2 Hyogo College of Medicine, Laboratory of Tumor Immunology and Cell Therapy, Nishinomiya, Hyogo, Japan (GRID:grid.272264.7) (ISNI:0000 0000 9142 153X)
3 Kobe University Graduate School of Medicine, Division of Cell Biology, Kobe, Hyogo, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077)
4 University of Bern, Interfaculty Bioinformatics Unit and Swiss Institute of Bioinformatics, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
5 Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (KI/AZ ICMC), Huddinge, Sweden (GRID:grid.5734.5)
6 University of Bern, Visceral Surgery Research Laboratory, Department of Biomedical Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
7 Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (KI/AZ ICMC), Huddinge, Sweden (GRID:grid.5734.5); Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Department of Immunology, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457)
8 National Institute for Physiological Sciences, Division of Cell Structure, Okazaki, Japan (GRID:grid.467811.d) (ISNI:0000 0001 2272 1771); School of Life Science, Department of Physiological Sciences, Okazaki, Japan (GRID:grid.467811.d)
9 Kyoto University Faculty of Medicine, Department of Cell Biology, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)